SEC Form 4 · accession 0001140361-17-012950
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph E Tyler
Officer — VP, Manufacturing
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.03 | Mar 20, 2017 | A | 39,000 | A | — | Mar 19, 2027 | Common Stock | 39,000 | 39,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning on April 20, 2017, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.